Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cogent Biosciences, Inc. (UMRX)
|
Add to portfolio |
|
|
|
| Price: |
$8.39
| | Metrics |
| OS: |
85.5
|
M
| |
|
|
| Market cap: |
$717
|
M
| |
|
|
|
Net cash:
|
$351
|
M
| |
$4.11
|
per share
|
|
EV:
|
$366
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($174)
|
M
| |
|
|
| EPS |
($1.72)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 121.6 | 0.0 | 55.9 | 7.9 | 22.5 | 9.7 | 8.4 |
| Revenue growth | | 117.5% | -100.0% | | -65.0% | 131.1% | 16.4% | -62.0% |
| Cost of goods sold | 147.8 | 147.8 | 75.6 | 75.6 | 90.1 | 54.7 | 0.0 | 0.0 |
| Gross profit | -147.8 | -26.2 | -75.6 | -19.6 | -82.2 | -32.2 | 9.7 | 8.4 |
| Gross margin | | -21.6% | | -35.1% | -1044.3% | -143.0% | 100.0% | 100.0% |
| Selling, general and administrative | 0.0 | | 0.0 | | | | | |
| Research and development | | | | | 25.7 | 43.7 | 38.3 | 29.8 |
| General and administrative | 0.0 | 26.2 | 0.0 | 19.6 | 17.4 | 11.0 | 7.5 | 4.7 |
| EBIT | -142.5 | -147.8 | -74.7 | -75.6 | -27.8 | -32.1 | -36.0 | -26.2 |
| EBIT margin | | -121.6% | | -135.1% | -353.1% | -142.7% | -369.9% | -312.8% |
| Pre-tax income | -140.2 | -140.2 | -72.3 | -72.3 | -74.8 | -31.8 | -34.5 | -25.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -140.2 | -140.2 | -72.3 | -72.3 | -179.2 | -31.8 | -34.5 | -25.6 |
| Net margin | | -115.3% | | -129.3% | -2276.8% | -141.5% | -354.9% | -305.7% |
| |
| Diluted EPS | ($2.39) | ($2.39) | ($1.87) | ($1.87) | ($16.17) | ($4.18) | ($1.39) | ($2.51) |
| Shares outstanding (diluted) | 58.7 | 58.7 | 38.7 | 38.7 | 11.1 | 7.6 | 24.9 | 10.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|